The award is for Support of existing NHSBT Low Density Lipid (LDL) Removal Apheresis.

Contract notice published on 10th March 2021 with publication reference: 2021/S 000-004887.

Please see section II.2.4 for detailed description of the procurement.

The Therapeutic Apheresis Services (TAS) function operates within the Clinical Services directorate of NHSBT. Multi-disciplinary TAS teams operate from eight regional hub units and three 3 spoke sites that are based within Acute NHS Trusts across England and South Wales. Each unit provides a portfolio of therapeutic treatments to both adult and paediatric patients from across a range of clinical specialities. Treatments provided include: Extracorporeal Photopheresis (ECP), Peripheral Blood Stem Cell (PBSC) Collection, Therapeutic Plasma Exchange (PEX), Red Cell Exchange (RCE), Low Density Lipid (LDL) Removal, Platelet / White Cell Depletion and Lymphocyte Collection.

The requirement for this procurement was for the supply of consumables and maintenance of the existing ART Universal machines. Contract notice published on 10th March 2021 with publication reference: 2021/S 000-004887.

As a result of the tender, a Framework Agreement for Support of existing NHSBT Low Density Lipid (LDL) Removal Apheresis for a period of 2 years with two 1-year options to extend has been awarded to Fresenius Medical Care (UK) Ltd.